Slide 1: Glenmark Life Sciences Investor Presentation Cover Letter
G qlenmaR.k LIFE SCIENCES Partnership. Innovation. Passion. November 10, 2021 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Sandra Kurla Complex, Fort, Mumbai -
Slide 2: Q2 FY22 Investor Presentation
Q2 FY22 Investor Presentation Glenmark Life Sciences Ltd G qlenma~k LIFE SCIENCES
Slide 3: Financial Performance Review
01 Financial Performance Review G qlenma~k LIFE SCIENCES
Slide 4: Q2 FY22 Highlights
Q2 FY22 -– Highlights ighlights • YoY Revenue grew at 7.9% in Q2 and Dr. Yasir Rawjee Revenue Managing Director 18.4% in H1 INR 5,618 mn and Chief • CDMO business rebound growing at Executive Officer 85.1% in Q2 and 25.2% in H1 t YoY, 7.9% t QoQ, 7.0% At Glenmark Life Sciences, both our generic API
Slide 5: P&L Highlights - Q2 FY22
P&L Highl gh s – P& Highlights - Q2 FY22 Amounts in INR Millions Q2 FY22 Q1 FY22 QoQ Q2 FY21 YoY H1 FY22 H1 FY21 YoY Revenue from Operations 5,617.6 5,249.0 7.0% 5,208.1 7.9% 10,866.6 9,177.7 18.4% Gross Profit 2,905.4 2,655.2 9.4% 2,268.3 28.1% 5,560.7 4,483.6 24.0% Gross Profit (%) 51.7% 50.6% 43.
Slide 6: Key Balance Sheet Items and Cash Flow
Key Balance Ba a ce Sheet S eet Items I ems and Cash Cas flow [ _ _] Key Balance Sheet Items [_ _ _] Free Cash Flow Amounts in INR Millions As at 30th As at 31st ------ Amounts in INR Millions H1 FY22 H1 FY21 FY21 Sep'21 Mar'21 Profit Before Tax 2,875.0 2,051.3 4,709.4 Equity 19,780.0 7,527.5 Adjust
Slide 7: Quarter on Quarter Performance
Quarter on Quarter Performance Sustained growth momentum and improving PAT margins after debt pay-down ------------------------------------ 5,618 ------------------------------------ 36.4% 30.2% 37 . 0% 31.0% 31.3% 5,208 5,249 1~ % 32 . 0% 5,002 4,672 1,500 24.4% 27 . 0% 22 . 0% 17 . 0% 1,702 1,694
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth trajectory with healthy profitability indicators ------------------------------------ 18,852 ------------------------------------ 35 . 0% 31.5% 31.4% 30.7% 6,000 30.6% 15,373 30 . 0% 14,050 5,000 27.6% 12,017 10,867 25 . 0% 4,000 5,919 20 . 0% 4,840 3
Slide 9: Strong Returns Indicators
Strong Returns Indicators ------------------------------- ROCE ------------------------------- Fixed Assets Turnover ---------------- --- - ---- Working Capital Days 33% 3.7 FY19 FY20 FY21 H1 FY22 33% 3.3 350 250 32% 300 202 2.9 173 176 200 31% 2.7 250 159 31% wir 2.5 200 150 100 104 98 99 85 150 10
Slide 10: Business Performance Review
02 Business Performance Review G qlenma~k LIFE SCIENCES
Slide 11: Segment Performance
Segment Segme Performance Performa ce 3.9% YoY 5.1% QoQ 85.1% YoY 26.1% QoQ 5,047 4,858 4,803 Revenue (₹ Mn) 4,675 Revenue (₹ Mn) 4,078 548 490 389 265 280 Generic API Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 CDMO Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 • Generic API revenues in Q2FY22 • CDMO revenue
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix 24% 27% 27% 33% 40% 37% 37% 43% 37% 45% 5% 6% 4% 4% 3% 8% 14% 3% 6% 7% 4% 7% 10% 14% 8% 76% 73% 63% 67% 60% 44% 47% 37% 40% 39% Market Mix --------------> Q2 FY21 Q3 FY21 Q4 FY21 ■ Regulated Markets Q1 FY22 Q2 FY22 ■ Emerging Markets Therapeutic ,______________) Area
Slide 13: Company Overview
03 Company Overview G qlenma~k LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint Filed 412 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 50+ 330+ 30+ 81 112 143 10+ 16 100+ 50+ 60 (Brazil) India – Mix of Regulated Number of Number of customers Regulated Markets Emerging Mark
Slide 15: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity (Mar-21) Last USFDA Inspection Date Approvals Mahape, Navi Mumbai USFDA, MHRA (UK), FIMEA R&D for new product development (Finland), Romania (Europe) and complex
Slide 16: R&D Capabilities
R&D Capabilities [ ---------------] 450 5.0% 400 405 400 376 4.5% Cumulative Filing Status 350 4.0% 300 275 3.5% North Therapy Europe Japan Brazil ROW Total 250 2.7% 2.6% 3.0% America 2.5% 200 2.1% 2.5% CVS 34 27 4 15 34 114 150 2.0% CNS 34 16 7 12 11 80 100 1.5% Diabetes 9 3 - 7 9 28 50 1.0% Pain M
Slide 17: Strategy Going Forward
04 Strategy Going Forward G qlenma~k 16 LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers • New product launches • Ramp up CDMO portfolio • Geographical expansion • Expand into complex API platforms • Focus on new markets becoming more • Iron compounds regulated • Oncology • Pursue 2nd source opportunities with top generic players Gx API New Growth Business levers
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Current Status & Planned Operational Expansion Type Division Location Capacity Capacity Timelines Under Construction Phase I – Q4FY22 Brownfield API Dahej 141.9 KL 4 Modules -240 KL Phase II – Q2 FY23 New plant Brownfield Intermediate Ankleshwar 550.2 KL Q2 FY23 400 KL
Slide 20: Thank You
Thank You Glenmark Life Sciences Limited Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai, 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: U74900PN2011PLC13996